查看購物車
  • Simplified Chinese
  • English
2021-2031年歐洲臨床試驗市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871413

2021-2031年歐洲臨床試驗市場報告：範圍、細分、動態和競爭分析

Europe Clinical Trials Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 136 Pages | 訂單完成後即時交付

價格

歐洲臨床試驗市場預計將大幅成長，到 2031 年將達到約 200.5653 億美元，高於 2023 年的 122.8673 億美元，在此期間的年複合成長率(CAGR) 為 6.3%。

執行摘要和市場分析

歐洲臨床試驗市場分為多個區域，包括英國、法國、德國、義大利、西班牙、波蘭、瑞士、瑞典、丹麥、比利時、荷蘭以及歐洲其他地區。該市場預期成長的驅動力是旨在開發新藥和推出創新產品的臨床試驗活動的增加。市場受益於健全的監管框架、完善的醫療保健基礎設施以及對罕見疾病和慢性病的高度關注。監管機構和政府強調透明度和患者安全，而與合約研究組織 (CRO) 的合作則提高了營運效率。然而，冗長的核准流程和高昂的成本等挑戰依然存在。

市場區隔分析

歐洲臨床試驗市場可以透過各種細分市場進行分析，包括研究設計、適應症和階段類型。

1. 研究設計：市場分為干涉性試驗和擴大准入試驗，其中干涉性試驗在 2023 年佔據更大的市場佔有率。

2. 適應症：市場細分為多個治療領域，包括自體免疫/發炎、疼痛管理、腫瘤、神經系統疾病、糖尿病、肥胖、代謝性疾病、心血管疾病等。 2023年，腫瘤領域佔最大佔有率。

3. 階段類型：市場分為 I 期、II 期和 III 期試驗，其中 II 期試驗在 2023 年佔據市場佔有率的主導地位。

市場展望

分散式臨床試驗 (DCT) 因其允許參與者無需頻繁前往醫院即可參與試驗而日益受到重視。這些試驗利用數位技術進行遠端資料收集、監測以及研究人員和參與者之間的溝通。結合居家和現場活動的混合模式也越來越受歡迎，這種模式能夠提升患者體驗並適應複雜的試驗方案。最初，DCT 的推廣應用面臨許多挑戰，例如對病患隱私、資料安全、監管問題以及複雜方案的擔憂。然而，新冠疫情加速了分散式和混合模式的轉變，因為傳統的線下試驗變得不再可行。麥肯錫的數據顯示，約 70% 的潛在臨床試驗參與者無需前往試驗中心，這凸顯了分散式模式對於覆蓋更廣泛、更多樣化的患者群體的重要性。

混合試驗透過將分散式試驗（DCT）要素融入研究設計，提供了更大的靈活性，吸引了更多申辦方，並重塑了臨床試驗格局。美國食品藥物管理局（FDA）預計2023年推出支持DCT方法的方案，進一步提升臨床研究的公信力。對分散式試驗和混合試驗日益成長的重視，預計將在未來幾年為臨床試驗市場創造豐厚的機會。

國家概況

歐洲臨床試驗市場涵蓋英國、德國、法國、西班牙、義大利、波蘭、瑞士、瑞典、丹麥、比利時、荷蘭等主要國家。截至2023年，德國是該市場的領頭羊，約佔2021年全球臨床試驗總量的3.9%。德國擁有龐大的患者群體，對高品質醫療保健的需求旺盛。為促進學術臨床研究，德國在聯邦教育與研究部的資助下，設立了臨床試驗協調中心。德國的臨床試驗由聯邦藥品和醫療器材研究所或保羅·埃爾利希研究所監管，確保核准流程標準化、可靠且透明，核准時間相對較短。德國的主要合約研究組織（CRO），例如Sofpromed和CONET GmbH，提供涵蓋各個階段和各種類型研究的全面臨床試驗服務。

公司簡介

臨床試驗市場的主要參與者包括QVIA Holdings Inc、Parexel International Corp、IXICO Plc、Charles River Laboratories International Inc、ICON Plc、藥明康德股份有限公司、SGS SA、Syneos Health Inc、Thermo Fisher Scientific Inc、Laboratory Corp of America Holdings、CliniRx Research Private Limited、Caidyaal.這些公司正在推行擴張、產品創新以及併購等策略，以增強其市場佔有率並為客戶提供創新解決方案。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：

第4章：歐洲臨床試驗市場－主要市場動態

  • 市場促進因素
    • 臨床研究外包實務與試驗數量大幅成長
    • 蓬勃發展的製藥業，研發活動激增
  • 市場限制
    • 昂貴且耗時的過程
  • 市場機遇
    • 採用分散式臨床試驗及混合式臨床試驗
  • 未來趨勢
    • 人工智慧驅動的臨床試驗

第5章：臨床試驗市場—歐洲分析

  • 2021-2031年歐洲臨床試驗市場收入
  • 歐洲臨床試驗市場預測分析

第6章：歐洲臨床試驗市場分析－依研究設計分類

  • 干預性試驗
  • 擴大使用試驗

第7章：歐洲臨床試驗市場分析－依適應症分類

  • 自體免疫/炎症
  • 疼痛管理
  • 腫瘤學
  • 神經系統疾病
  • 糖尿病
  • 肥胖
  • 代謝紊亂
  • 心血管
  • 其他

第8章：歐洲臨床試驗市場分析－以階段類型分類

  • 第一階段
  • 第二階段
  • 第三階段

第9章：歐洲臨床試驗市場—國家分析

  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 波蘭
    • 瑞士
    • 瑞典
    • 丹麥
    • 比利時
    • 荷蘭
    • 歐洲其他地區

第10章：競爭格局

  • 關鍵參與者熱力圖分析
  • 公司定位與集中度

第11章：行業概況

  • 概述
  • 臨床試驗市場成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章：公司簡介

  • QVIA Holdings Inc
  • Parexel International Corp
  • IXICO Plc
  • Charles River Laboratories International Inc
  • ICON Plc
  • WuXi AppTec Co Ltd
  • SGS SA
  • Syneos Health Inc
  • SIRO Clinpharm Pvt Ltd
  • Thermo Fisher Scientific Inc
  • Laboratory Corp of America Holdings
  • CliniRx Research Private Limited
  • Caidya
  • Oracle Corp
  • Medpace Holdings Inc

第13章：附錄

Product Code: BMIRE00028989

The clinical trials market in Europe is projected to grow significantly, reaching approximately USD 20,056.53 million by 2031, up from USD 12,286.73 million in 2023, reflecting a compound annual growth rate (CAGR) of 6.3% during this period.

Executive Summary and Market Analysis

The European clinical trials market is divided into several regions, including the UK, France, Germany, Italy, Spain, Poland, Switzerland, Sweden, Denmark, Belgium, the Netherlands, and other parts of Europe. The anticipated growth in this market is driven by an increase in clinical trial activities aimed at developing new drugs and launching innovative products. The market benefits from strong regulatory frameworks, a robust healthcare infrastructure, and a heightened focus on addressing rare and chronic diseases. Regulatory bodies and governments emphasize transparency and patient safety, while collaborations with contract research organizations (CROs) enhance operational efficiency. However, challenges such as lengthy approval processes and high costs persist.

Market Segmentation Analysis

The Europe clinical trials market can be analyzed through various segments, including study design, indications, and phase type.

1. Study Design: The market is categorized into interventional trials and expanded access trials, with interventional trials holding a larger market share in 2023.

2. Indications: The market is segmented into various therapeutic areas, including autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular diseases, and others. Oncology represented the largest share in 2023.

3. Phase Type: The market is divided into phase I, phase II, and phase III trials, with phase II trials dominating the market share in 2023.

Market Outlook

Decentralized clinical trials (DCTs) are gaining traction as they allow participants to engage in trials without frequent visits to hospital sites. These trials utilize digital technologies for remote data collection, monitoring, and communication between researchers and participants. A hybrid approach, which combines home-based and on-site activities, is also becoming popular, enhancing patient experience and accommodating complex protocols. Initially, the adoption of DCTs faced hurdles such as concerns over patient privacy, data security, regulatory issues, and intricate protocols. However, the COVID-19 pandemic accelerated the shift towards decentralized and hybrid methods, as traditional in-person trials became impractical. Data from McKinsey indicates that around 70% of potential clinical trial participants do not visit trial sites, highlighting the need for decentralization to access a broader and more diverse patient population.

Hybrid trials offer flexibility by integrating DCT elements into study designs, attracting more sponsors and reshaping the clinical trial landscape. The FDA is expected to introduce protocols supporting DCT methods in 2023, further enhancing the credibility of clinical research. The growing emphasis on decentralized and hybrid trials is anticipated to create lucrative opportunities for the clinical trials market in the coming years.

Country Insights

The European clinical trials market includes key countries such as the UK, Germany, France, Spain, Italy, Poland, Switzerland, Sweden, Denmark, Belgium, the Netherlands, and others. Germany is the leading country in this market as of 2023, accounting for approximately 3.9% of global clinical trials conducted in 2021. The country boasts a large patient population and a strong demand for high-quality healthcare. To promote academic clinical research, Germany has established coordinating centers for clinical trials under a funding initiative from the Federal Ministry of Education and Research. Clinical trials in Germany are regulated by the Federal Institute for Drugs and Medical Devices or the Paul-Ehrlich Institute, ensuring standardized, reliable, and transparent approval processes with relatively short timelines. Major CROs in Germany, such as Sofpromed and CONET GmbH, provide comprehensive clinical trial services across various phases and types of studies.

Company Profiles

Key players in the clinical trials market include QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx Research Private Limited, Caidya, Oracle Corp, Medpace Holdings Inc, and SIRO Clinpharm Pvt Ltd. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to clients.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Clinical Trials Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials
    • 4.1.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities
  • 4.2 Market Restraints
    • 4.2.1 Expensive and Time-Consuming Process
  • 4.3 Market Opportunities
    • 4.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
  • 4.4 Future Trends
    • 4.4.1 AI-Driven Clinical Trials

5. Clinical Trials Market - Europe Analysis

  • 5.1 Europe Clinical Trials Market Revenue (US$ Million), 2021-2031
  • 5.2 Europe Clinical Trials Market Forecast Analysis

6. Europe Clinical Trials Market Analysis - by Study Design

  • 6.1 Interventional Trials
    • 6.1.1 Overview
    • 6.1.2 Interventional Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Expanded Access Trials
    • 6.2.1 Overview
    • 6.2.2 Expanded Access Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Clinical Trials Market Analysis - by Indications

  • 7.1 Autoimmune/Inflammation
    • 7.1.1 Overview
    • 7.1.2 Autoimmune/Inflammation: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Pain Management
    • 7.2.1 Overview
    • 7.2.2 Pain Management: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Oncology
    • 7.3.1 Overview
    • 7.3.2 Oncology: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Neurological Disorders
    • 7.4.1 Overview
    • 7.4.2 Neurological Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Diabetes
    • 7.5.1 Overview
    • 7.5.2 Diabetes: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Obesity
    • 7.6.1 Overview
    • 7.6.2 Obesity: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.7 Metabolic Disorders
    • 7.7.1 Overview
    • 7.7.2 Metabolic Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.8 Cardiovascular
    • 7.8.1 Overview
    • 7.8.2 Cardiovascular: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.9 Others
    • 7.9.1 Overview
    • 7.9.2 Others: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Clinical Trials Market Analysis - by Phase Type

  • 8.1 Phase I
    • 8.1.1 Overview
    • 8.1.2 Phase I: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Phase II
    • 8.2.1 Overview
    • 8.2.2 Phase II: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Phase III
    • 8.3.1 Overview
    • 8.3.2 Phase III: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Clinical Trials Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Clinical Trials Market Overview
    • 9.1.2 Europe Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 9.1.2.1 Europe Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 9.1.2.2 United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.2.1 United Kingdom: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.2.2 United Kingdom: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.2.3 United Kingdom: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.3 Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.3.1 Germany: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.3.2 Germany: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.3.3 Germany: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.4 France: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.4.1 France: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.4.2 France: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.4.3 France: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.5 Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.5.1 Spain: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.5.2 Spain: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.5.3 Spain: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.6 Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.6.1 Italy: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.6.2 Italy: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.6.3 Italy: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.7 Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.7.1 Poland: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.7.2 Poland: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.7.3 Poland: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.8 Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.8.1 Switzerland: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.8.2 Switzerland: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.8.3 Switzerland: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.9 Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.9.1 Sweden: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.9.2 Sweden: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.9.3 Sweden: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.10 Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.10.1 Denmark: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.10.2 Denmark: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.10.3 Denmark: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.11 Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.11.1 Belgium: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.11.2 Belgium: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.11.3 Belgium: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.12 Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.12.1 Netherlands: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.12.2 Netherlands: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.12.3 Netherlands: Europe Clinical Trials Market Share - by Phase Type
      • 9.1.2.13 Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.2.13.1 Rest of Europe: Europe Clinical Trials Market Share - by Study Design
        • 9.1.2.13.2 Rest of Europe: Europe Clinical Trials Market Share - by Indications
        • 9.1.2.13.3 Rest of Europe: Europe Clinical Trials Market Share - by Phase Type

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Positioning and Concentration

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Clinical Trials Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 QVIA Holdings Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Parexel International Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 IXICO Plc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Charles River Laboratories International Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 ICON Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 WuXi AppTec Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 SGS SA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Syneos Health Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SIRO Clinpharm Pvt Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Thermo Fisher Scientific Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Laboratory Corp of America Holdings
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 CliniRx Research Private Limited
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments
  • 12.13 Caidya
    • 12.13.1 Key Facts
    • 12.13.2 Business Description
    • 12.13.3 Products and Services
    • 12.13.4 Financial Overview
    • 12.13.5 SWOT Analysis
    • 12.13.6 Key Developments
  • 12.14 Oracle Corp
    • 12.14.1 Key Facts
    • 12.14.2 Business Description
    • 12.14.3 Products and Services
    • 12.14.4 Financial Overview
    • 12.14.5 SWOT Analysis
    • 12.14.6 Key Developments
  • 12.15 Medpace Holdings Inc
    • 12.15.1 Key Facts
    • 12.15.2 Business Description
    • 12.15.3 Products and Services
    • 12.15.4 Financial Overview
    • 12.15.5 SWOT Analysis
    • 12.15.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 List of Abbreviations

List Of Tables

  • Table 1. Europe Clinical Trials Market Segmentation
  • Table 2. Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Study Design
  • Table 4. Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indications
  • Table 5. Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Phase Type
  • Table 6. Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 7. United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 8. United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 9. United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 10. Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 11. Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 12. Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 13. France: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 14. France: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 15. France: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 16. Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 17. Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 18. Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 19. Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 20. Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 21. Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 22. Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 23. Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 24. Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 25. Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 26. Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 27. Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 28. Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 29. Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 30. Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 31. Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 32. Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 33. Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 34. Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 35. Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 36. Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 37. Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 38. Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 39. Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 40. Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Study Design
  • Table 41. Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Indications
  • Table 42. Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021 - 2031(US$ Million) - by Phase Type
  • Table 43. Recent Organic Growth Strategies in Clinical Trials Market
  • Table 44. Recent Inorganic Growth Strategies in the Clinical Trials Market
  • Table 45. List of Abbreviations

List Of Figures

  • Figure 1. Europe Clinical Trials Market Segmentation - Country
  • Figure 2. Europe Clinical Trials Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Clinical Trials Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Clinical Trials Market Share (%) - by Study Design (2023 and 2031)
  • Figure 6. Interventional Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Expanded Access Trials: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Europe Clinical Trials Market Share (%) - by Indications (2023 and 2031)
  • Figure 9. Autoimmune/Inflammation: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Pain Management: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Oncology: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Neurological Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Diabetes: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Obesity: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Metabolic Disorders: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Cardiovascular: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Others: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Europe Clinical Trials Market Share (%) - by Phase Type (2023 and 2031)
  • Figure 19. Phase I: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Phase II: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Phase III: Europe Clinical Trials Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Europe Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. United Kingdom: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Germany: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. France: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Spain: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Italy: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Poland: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 29. Switzerland: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 30. Sweden: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 31. Denmark: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 32. Belgium: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 33. Netherlands: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 34. Rest of Europe: Europe Clinical Trials Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 35. Heat Map Analysis by Key Players
  • Figure 36. Company Positioning and Concentration
  • Figure 37. Growth Strategies in Clinical Trials Market